Pfizer Demands FDA Give Emergency Use Authorization for Booster Shots for Kids Under 5

https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-submit-application-us-fda-emergency-use-1 

If authorized, children in this age group would receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-µg dose of the Omicron BA.4/BA.5-adapted bivalent vaccine. An application to extend Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine marketing authorization in the EU to include children ages 6 months through 4 years is under discussion with the European Medicines Agency (EMA).